GI Cancers:

IRB #H-38168/ DFCI El Centro: Engaging Latinos in the Center of Cancer Treatment options – RCT of Usual Chemotherapy Educational Tools Versus Investigational Chemotherapy Educational Tools (pending IRB approval)


CIRB #H-37277/ CTSU #A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair


CIRB #H-38045 / CTSU #A021602 (CABINET):  Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Everolimus

HIRB #H-38781/ TARVEDA #PEN-221:  A Phase 1/2a, open label multicenter study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PEN-221 in patients with somatostatin receptor 2 expressing advanced cancers, including gastroenteropancreatic or lung or thymus or other neuroendocrine tumors or small cell lung cancer or large cell neuroendocrine carcinoma of lung (not yet submitted to IRB)


CIRB #H-38309/ CTSU #EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer


IRB #H-38609/ Merck #KEYNOTE-937: A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection or Local Ablation (KEYNOTE-937) (pending IRB approval)

IRB #H-38410/ Incyte #INCB 54828-302: A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (not yet submitted to IRB)